BioScrip (BIOS) Lifted to Buy at BidaskClub

BidaskClub upgraded shares of BioScrip (NASDAQ:BIOS) from a hold rating to a buy rating in a research report report published on Friday.

A number of other research firms also recently weighed in on BIOS. Canaccord Genuity began coverage on BioScrip in a research report on Wednesday, December 12th. They set a buy rating and a $5.00 target price on the stock. TheStreet raised BioScrip from a d+ rating to a c- rating in a research report on Monday, November 26th. Lake Street Capital lifted their target price on BioScrip from $4.50 to $10.00 and gave the stock a buy rating in a research report on Friday, December 7th. Zacks Investment Research downgraded BioScrip from a hold rating to a sell rating in a research report on Thursday, January 3rd. Finally, Barrington Research restated a buy rating and set a $4.00 price target on shares of BioScrip in a research note on Friday, October 5th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $4.88.

BIOS stock opened at $3.85 on Friday. BioScrip has a twelve month low of $2.31 and a twelve month high of $4.14. The stock has a market cap of $510.88 million, a P/E ratio of -8.75 and a beta of 0.61.

BioScrip (NASDAQ:BIOS) last released its earnings results on Tuesday, November 6th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). The company had revenue of $181.00 million during the quarter, compared to analyst estimates of $171.35 million. During the same quarter in the previous year, the business posted ($0.12) earnings per share. The firm’s quarterly revenue was down 8.9% compared to the same quarter last year. Analysts anticipate that BioScrip will post -0.33 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in BIOS. Metropolitan Life Insurance Co. NY lifted its stake in BioScrip by 77.3% during the second quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock worth $132,000 after purchasing an additional 19,625 shares during the period. Engineers Gate Manager LP bought a new position in BioScrip during the third quarter worth about $146,000. MetLife Investment Advisors LLC lifted its stake in BioScrip by 220.8% during the second quarter. MetLife Investment Advisors LLC now owns 64,727 shares of the company’s stock worth $190,000 after purchasing an additional 44,548 shares during the period. Citadel Advisors LLC lifted its stake in BioScrip by 471.9% during the third quarter. Citadel Advisors LLC now owns 66,502 shares of the company’s stock worth $206,000 after purchasing an additional 54,874 shares during the period. Finally, B. Riley Wealth Management Inc. bought a new position in BioScrip during the third quarter worth about $326,000. Hedge funds and other institutional investors own 82.09% of the company’s stock.

BioScrip Company Profile

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

See Also: Earnings Per Share (EPS) Explained

Analyst Recommendations for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply